PMID: 16503865Mar 1, 2006Paper

Cholesterol absorption blockade with ezetimibe

Current Drug Targets. Cardiovascular & Haematological Disorders
Peter P Toth, Michael H Davidson

Abstract

The reduction of circulating atherogenic lipoproteins through lifestyle modification and pharmacologic intervention is an important therapeutic goal in patients at risk for acute cardiovascular events. A large number of clinical trials have demonstrated that the reduction of low-density lipoprotein cholesterol (LDL-C) is associated with significant decreases in the incidence of all cause mortality, stroke, fatal and nonfatal myocardial infarction, and the need for revascularization with coronary artery bypass grafting and percutaneous transluminal coronary angioplasty. Therapy with 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (i.e., statins) are the agents of choice for treating a variety of dyslipidemias, particularly when LDL-C levels are elevated. The statins are highly efficacious; however, not all patients are able to tolerate the higher doses of these medications due to adverse side-effects such as hepatoxicity and myotoxicity. Moreover, many patients cannot achieve their various lipoprotein targets at even the highest doses of these medications. Ezetimibe is a novel cholesterol absorption inhibitor that blocks the translocation of dietary and biliary cholesterol from the gastrointestinal lumen int...Continue Reading

Citations

Mar 14, 2007·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Nabil G Seidah, Annik Prat
Sep 28, 2006·Cardiovascular Diabetology·Alexander TenenbaumYehuda Adler
Aug 23, 2012·Vascular Health and Risk Management·Binh An P PhanPeter P Toth
Nov 17, 2012·World Journal of Gastroenterology : WJG·Assaf SteinFred M Konikoff
Nov 16, 2006·Expert Opinion on Therapeutic Targets·Irene F Gazi, Dimitri P Mikhailidis
Apr 12, 2008·Expert Review of Cardiovascular Therapy·Harold E BaysAndrew M Tershakovec
Jul 10, 2008·Expert Opinion on Drug Metabolism & Toxicology·Minna T JänisMatej Oresic
Feb 16, 2010·European Journal of Pharmacology·Michalis KalogirouMoses Elisaf
Dec 23, 2008·Transplantation Proceedings·M L Rodríguez-Ferrero, F Anaya
Oct 1, 2008·Journal of Clinical Lipidology·Hanna Slim, Paul D Thompson
Mar 18, 2016·Vascular and Endovascular Surgery·Lorena GonzalezVivian Gahtan
Aug 24, 2017·Praxis·Jens Barthelmes, Isabella Sudano
Aug 31, 2013·Diabetes & Metabolism Journal·Sung-Woo Park
Jun 20, 2020·Expert Opinion on Pharmacotherapy·Hani EssaGregory Y H Lip
Dec 14, 2018·Cardiology and Therapy·Keshav Kumar GuptaRanjodh Singh Sanghera
Oct 9, 2019·Porto Biomedical Journal·Gerhard P Püschel, Janin Henkel
Feb 19, 2021·Future Cardiology·Rama HritaniAnandita Agarwala

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.